Verrica Pharmaceuticals (Verrica Pharmaceuticals) Total Assets : $81.60 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Verrica Pharmaceuticals Total Assets?

Verrica Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was $81.60 Mil.

During the past 12 months, Verrica Pharmaceuticals's average Total Assets Growth Rate was 15.30% per year. During the past 3 years, the average Total Assets Growth Rate was 11.50% per year. During the past 5 years, the average Total Assets Growth Rate was 34.30% per year.

During the past 8 years, Verrica Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 622.30%. The lowest was 11.50%. And the median was 67.00%.

Total Assets is connected with ROA %. Verrica Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2023 was -110.16%. Total Assets is also linked to Revenue through Asset Turnover. Verrica Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 was 0.02.

Verrica Pharmaceuticals Total Assets Historical Data

The historical data trend for Verrica Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verrica Pharmaceuticals Total Assets Chart

Verrica Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

68.42

74.15

80.13

44.72

81.60

Verrica Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Assets	Get a 7-Day Free Trial															44.72	68.64	62.20	97.15	81.60

Verrica Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Verrica Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	19.763	+	61.834
	=	81.60

Verrica Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	19.763	+	61.834
	=	81.60

Verrica Pharmaceuticals (NAS:VRCA) Total Assets Explanation

Total Assets is connected with ROA %.

Verrica Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	-98.456	/	( (97.148	+	81.597)	/ 2 )
	=	-98.456	/	89.3725
	=	-110.16 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Verrica Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	1.988	/	( (97.148	+	81.597)	/ 2 )
=	1.988	/	89.3725
=	0.02

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Verrica Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of Verrica Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Verrica Pharmaceuticals (Verrica Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verrica Pharmaceuticals Inc (NAS:VRCA) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

1NE:Germany

Address

44 West Gay Street, Suite 400, West Chester, PA, USA, 19380

Website

https://www.verrica.com

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its lead product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a highly contagious and primarily pediatric viral skin disease, and common warts.

Executives

Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Ted White	director, officer: President and CEO	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Terry Kohler	officer: Chief Financial Officer	C/O VERRICA PHARMACEUTICALS INC., 44 WEST GAY STREET, SUITE 400, WEST CHESTER PA 19380
Christopher G. Hayes	officer: General Counsel	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Joe Bonaccorso	officer: Chief Commercial Officer	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Paul B Manning	director, 10 percent owner	200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Gary Goldenberg	director	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
A Brian Davis	officer: Chief Financial Officer	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Craig Ballaron	director	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Stalfort John A Iii	director	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Lawrence Eichenfield	director	C/O FORTE BIOSCIENCES, INC., 1124 W. CARSON ST., MRL BLDG 3-320, TORRANCE CA 90502
Diem Nguyen	director	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Matt Davidson	10 percent owner	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Linda Palczuk	officer: Chief Operating Officer	7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD 21046
Chris Degnan	officer: Chief Financial Officer	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380